Mobile

A one year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low pro...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-010403-84

A one year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low probability of response – the GErman PAnobinostat low Risk MDS trial

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the hematological improvement of the erythropoietic system (HI-E) using modified IWG criteria in patients treated for 4 months with LBH589 single agent.

Critère d'inclusion

  • myelodysplastic syndrome

Liens